$CHAD

White Parker purchased $90K of CHAD

White Parker purchased 10,000 shares of DeFi Development Corp. (CHAD) at an average of $8.96 ($8.90–$8.96) across 2 trades over 2026-09-24 to 2026-09-25.

Original reporting
SEC EDGAR · White Parker
Published Sep 25, 2026, 6:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CHAD
Bullish
low confidence
Mentioned
$CHAD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CHADBullishLow
01

Why it matters

Traders may monitor follow-on insider activity and whether the purchase is part of a broader accumulation pattern, but there is no new business information here.

02

Market read

A disclosed insider buy can modestly improve sentiment, but without additional fundamental catalysts it is unlikely to drive a sustained repricing.

03

What to watch

The filing does not indicate intent, timing constraints, or whether the insider’s broader position changed beyond the disclosed post-trade holdings.

Relevance 4/10Novelty 6/10Timing: SEC Form 4 filed 2026-09-25 (after-hours/late day disclosure).

Background

The article is an SEC Form 4 insider transaction disclosure for DeFi Development Corp. (CHAD).

Company-level read

Ticker impact

$CHADBullishLow confidence
Context

White Parker, a 10% owner, bought 10,000 CHAD shares in open-market trades at about $8.90 to $8.96 per share, per Form 4.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than valuation-driven.

Evidence & confidence

Form 4 insider buys can be read as bullish, but the article provides no accompanying operational catalyst, guidance, or material corporate event, and the transaction value is under $0.1M.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be routine liquidity or diversification rather than a strong forward-looking signal, especially without a stated rationale.

Key entities

  • DeFi Development Corp.

    Subject of the Form 4 insider purchase disclosure (CHAD).

  • White Parker

    10% owner who purchased 10,000 shares via two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFDVMed

DeFi Development Corp. (CHAD): DFDV Preliminary Q3’26 Estimates Indicate Double-Digit SPS Growth and More Than 100% NAV Per Share Growth In Q3; SOL Treasury Growth Rises to 11% Since…

DeFi Development Corp. (CHAD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 October 5, 2026 DFDV Preliminary Q3’26 Estimates Indicate Double-Digit SPS Growth and More Than 100% NAV Per Share Growth In Q3; SOL Treasury Growth Rises to 11% Since August 12 Continued purchases and organic accumulation drive approximately 11% growth in SOL holdin

$DFDVMed

DFDV Expands SOL Treasury to 2.39 Million SOL and Establishes $300 Million CHAD ATM to Fuel Continued Growth

DeFi Development Corp. (CHAD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 September 14, 2026 DFDV Expands SOL Treasury to 2.39 Million SOL and Establishes $300 Million CHAD ATM to Fuel Continued Growth Quarter-to-date, SOL has outperformed the Nasdaq-100 by 39%, and DFDV has outperformed SOL by 2x over that same period CHAD ATM issuance is

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).